Understanding how to keep leukemia in remission for longer in older patients remains a significant challenge in cancer ...

The regulatory move applies only to trials of magrolimab given alongside Bristol-Myers Squibb's Vidaza (azacitidine), and stems from an "imbalance" in investigator-reported serious adverse events ...

If you are worried about using this medicine, speak to your doctor or pharmacist. Azacitidine-Teva contains the active ingredient azacitidine. Azacitidine-Teva is used to treat myelodysplastic ...

EST/21:30 CET– ImCheck Therapeutics announced today it will present updated results from its ongoing open-label, randomized ...

Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of care Triplet Combination with mipletamig continues to outperform ...

Aptevo Therapeutics reports strong remission rates in AML patients using mipletamig plus ven/aza, with Cohort 2 enrollment ...

Aptevo Therapeutics (APVO) announced two additional frontline AML patients have achieved remission within 30 days of treatment in the Company’s ...

The phase III SELECT-MDS-1 study evaluated tamibarotene in combination with azacitidine, a chemotherapy, in newly diagnosed ...

In total, 9 of 10 frontline patients across two trials achieved remission* when receiving the triplet combination of mipletamig + venetoclax + azacitidine (ven/aza). Notably, no CRS has been reported ...

Celgene’s pipeline has delivered another new drug filing for Bristol-Myers Squibb, thanks to positive results for oral azacitidine formulation CC-486 in the phase 3 QUAZAR AML-001 trial.